IL175522A0 - Substituted triazoles as sodium channel blockers - Google Patents
Substituted triazoles as sodium channel blockersInfo
- Publication number
- IL175522A0 IL175522A0 IL175522A IL17552206A IL175522A0 IL 175522 A0 IL175522 A0 IL 175522A0 IL 175522 A IL175522 A IL 175522A IL 17552206 A IL17552206 A IL 17552206A IL 175522 A0 IL175522 A0 IL 175522A0
- Authority
- IL
- Israel
- Prior art keywords
- pain
- alone
- pharmaceutically acceptable
- effective amount
- compounds
- Prior art date
Links
- 239000003195 sodium channel blocking agent Substances 0.000 title 1
- 150000003852 triazoles Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 6
- 208000002193 Pain Diseases 0.000 abstract 3
- 208000020925 Bipolar disease Diseases 0.000 abstract 2
- 208000019695 Migraine disease Diseases 0.000 abstract 2
- 239000003937 drug carrier Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 206010027599 migraine Diseases 0.000 abstract 2
- 208000000094 Chronic Pain Diseases 0.000 abstract 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 abstract 1
- 206010019233 Headaches Diseases 0.000 abstract 1
- 206010065390 Inflammatory pain Diseases 0.000 abstract 1
- 108010052164 Sodium Channels Proteins 0.000 abstract 1
- 102000018674 Sodium Channels Human genes 0.000 abstract 1
- 208000005298 acute pain Diseases 0.000 abstract 1
- 208000028683 bipolar I disease Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 231100000869 headache Toxicity 0.000 abstract 1
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 1
- 238000002690 local anesthesia Methods 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 230000036407 pain Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- -1 triazole compounds Chemical class 0.000 abstract 1
- 208000009935 visceral pain Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51889003P | 2003-11-10 | 2003-11-10 | |
| PCT/US2004/037280 WO2005047270A2 (en) | 2003-11-10 | 2004-11-05 | Substituted triazoles as sodium channel blockers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL175522A0 true IL175522A0 (en) | 2006-09-05 |
Family
ID=34590316
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL175522A IL175522A0 (en) | 2003-11-10 | 2006-05-09 | Substituted triazoles as sodium channel blockers |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20090074890A1 (enExample) |
| EP (1) | EP1694654B1 (enExample) |
| JP (1) | JP2007510741A (enExample) |
| KR (1) | KR20060123739A (enExample) |
| CN (1) | CN1922156A (enExample) |
| AT (1) | ATE500234T1 (enExample) |
| AU (1) | AU2004289694B2 (enExample) |
| BR (1) | BRPI0416319A (enExample) |
| CA (1) | CA2545254A1 (enExample) |
| DE (1) | DE602004031667D1 (enExample) |
| IL (1) | IL175522A0 (enExample) |
| IS (1) | IS8438A (enExample) |
| NO (1) | NO20062676L (enExample) |
| NZ (1) | NZ547044A (enExample) |
| RU (1) | RU2372339C2 (enExample) |
| WO (1) | WO2005047270A2 (enExample) |
| ZA (1) | ZA200603583B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR044503A1 (es) * | 2003-03-18 | 2005-09-14 | Merck & Co Inc | Triazoles sustituidos con biarilo como bloqueantes del canal de sodio |
| AU2004289694B2 (en) * | 2003-11-10 | 2010-05-13 | Merck Sharp & Dohme Corp. | Substituted triazoles as sodium channel blockers |
| GB0525068D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| GB0603008D0 (en) * | 2006-02-14 | 2006-03-29 | Portela & Ca Sa | Method |
| KR100808551B1 (ko) | 2006-12-01 | 2008-03-03 | 한국생명공학연구원 | 트리아졸 유도체를 유효성분으로 함유하는 대사성 질환 예방 및 치료용 약학적 조성물 |
| BRPI0807219A2 (pt) * | 2007-02-08 | 2015-05-26 | Synta Pharmaceuticals Corp | Composto de tiazol que modulam a atividade de hsp90 |
| EP2529624A3 (en) * | 2007-04-03 | 2013-03-13 | E. I. du Pont de Nemours and Company | Substituted benzene fungicides |
| JP5613565B2 (ja) * | 2007-10-25 | 2014-10-22 | リバルシオ コーポレイション | 細胞膜媒介細胞内シグナル伝達を調節するための組成物および方法 |
| CA2703648A1 (en) * | 2007-10-25 | 2009-04-30 | Revalesio Corporation | Bacteriostatic or bacteriocidal compositions and methods |
| EP2222639A1 (en) | 2007-11-21 | 2010-09-01 | Decode Genetics EHF | Biaryl pde4 inhibitors for treating pulmonary and cardiovascular disorders |
| EP2222638A2 (en) * | 2007-11-21 | 2010-09-01 | Decode Genetics EHF | Biaryl pde4 inhibitors for treating inflammation |
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| EP2531510B1 (en) | 2010-02-01 | 2014-07-23 | Novartis AG | Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists |
| AR080056A1 (es) | 2010-02-01 | 2012-03-07 | Novartis Ag | Derivados de ciclohexil-amida como antagonistas de los receptores de crf |
| US8835444B2 (en) | 2010-02-02 | 2014-09-16 | Novartis Ag | Cyclohexyl amide derivatives as CRF receptor antagonists |
| UY34094A (es) | 2011-05-27 | 2013-01-03 | Novartis Ag | Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina |
| TW201348235A (zh) | 2012-05-03 | 2013-12-01 | Novartis Ag | 作爲格瑞啉受體促效劑之３－螺環哌啶衍生物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3682075B2 (ja) * | 1993-04-16 | 2005-08-10 | クミアイ化学工業株式会社 | トリアゾール誘導体及び殺虫、殺ダニ剤 |
| TW533205B (en) * | 1996-06-25 | 2003-05-21 | Novartis Ag | Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition |
| IT1300055B1 (it) * | 1998-04-17 | 2000-04-05 | Boehringer Ingelheim Italia | Eterocicli con anello a 5 termini difenil-sostituiti loro procedimento di preparazione e loro impiego come farmici |
| AR029489A1 (es) * | 2000-03-10 | 2003-07-02 | Euro Celtique Sa | Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento |
| BR0108819A (pt) * | 2000-03-24 | 2002-12-10 | Euro Celtique Sa | Pirazóis triazóis e tetrazóis substituìdos de arila, e o uso dos mesmos |
| AR037233A1 (es) * | 2001-09-07 | 2004-11-03 | Euro Celtique Sa | Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento |
| AR044503A1 (es) * | 2003-03-18 | 2005-09-14 | Merck & Co Inc | Triazoles sustituidos con biarilo como bloqueantes del canal de sodio |
| US20060183897A1 (en) * | 2003-03-18 | 2006-08-17 | Chakravarty Prasun K | Biaryl substituted triazoles as sodium channel blockers |
| AU2004289694B2 (en) * | 2003-11-10 | 2010-05-13 | Merck Sharp & Dohme Corp. | Substituted triazoles as sodium channel blockers |
-
2004
- 2004-11-05 AU AU2004289694A patent/AU2004289694B2/en not_active Ceased
- 2004-11-05 KR KR1020067009120A patent/KR20060123739A/ko not_active Ceased
- 2004-11-05 WO PCT/US2004/037280 patent/WO2005047270A2/en not_active Ceased
- 2004-11-05 US US10/578,950 patent/US20090074890A1/en not_active Abandoned
- 2004-11-05 NZ NZ547044A patent/NZ547044A/en unknown
- 2004-11-05 AT AT04800897T patent/ATE500234T1/de not_active IP Right Cessation
- 2004-11-05 CN CNA2004800329352A patent/CN1922156A/zh active Pending
- 2004-11-05 DE DE602004031667T patent/DE602004031667D1/de not_active Expired - Lifetime
- 2004-11-05 RU RU2006120426/04A patent/RU2372339C2/ru not_active IP Right Cessation
- 2004-11-05 EP EP04800897A patent/EP1694654B1/en not_active Expired - Lifetime
- 2004-11-05 JP JP2006539729A patent/JP2007510741A/ja not_active Ceased
- 2004-11-05 CA CA002545254A patent/CA2545254A1/en not_active Abandoned
- 2004-11-05 BR BRPI0416319-2A patent/BRPI0416319A/pt not_active Application Discontinuation
- 2004-11-10 US US10/985,592 patent/US7459475B2/en not_active Expired - Lifetime
-
2006
- 2006-05-04 IS IS8438A patent/IS8438A/is unknown
- 2006-05-05 ZA ZA200603583A patent/ZA200603583B/xx unknown
- 2006-05-09 IL IL175522A patent/IL175522A0/en unknown
- 2006-06-09 NO NO20062676A patent/NO20062676L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1694654B1 (en) | 2011-03-02 |
| US20090074890A1 (en) | 2009-03-19 |
| RU2372339C2 (ru) | 2009-11-10 |
| CN1922156A (zh) | 2007-02-28 |
| AU2004289694B2 (en) | 2010-05-13 |
| RU2006120426A (ru) | 2007-12-27 |
| NZ547044A (en) | 2010-05-28 |
| ATE500234T1 (de) | 2011-03-15 |
| NO20062676L (no) | 2006-08-10 |
| WO2005047270A2 (en) | 2005-05-26 |
| ZA200603583B (en) | 2007-08-29 |
| IS8438A (is) | 2006-05-04 |
| US20060020006A1 (en) | 2006-01-26 |
| KR20060123739A (ko) | 2006-12-04 |
| US7459475B2 (en) | 2008-12-02 |
| DE602004031667D1 (de) | 2011-04-14 |
| EP1694654A2 (en) | 2006-08-30 |
| WO2005047270A3 (en) | 2005-09-22 |
| JP2007510741A (ja) | 2007-04-26 |
| AU2004289694A1 (en) | 2005-05-26 |
| CA2545254A1 (en) | 2005-05-26 |
| BRPI0416319A (pt) | 2007-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JO2480B1 (en) | Triple aryl substituted with aryl as a sodium channel blocking agent | |
| IL175522A0 (en) | Substituted triazoles as sodium channel blockers | |
| WO2004084824A3 (en) | Biaryl substituted 6-membered heterocyles as sodium channel blockers | |
| HU9603592D0 (en) | Aryl-sulfonamido-hydroxamic acids of matrix-metalloproteinase-inhibiting activity | |
| WO2007145922A3 (en) | Benzazepinones as sodium channel blockers | |
| MXPA05009611A (es) | Piperidinas sustituidas como nuevos inhibidores de mdm2-p53. | |
| WO2005030766A8 (en) | Phenyl - carboxamide compounds useful for treating pain | |
| PL1664016T3 (pl) | Środki terapeutyczne przydatne do leczenia bólu | |
| WO2007075524A3 (en) | Substituted piperidines as calcium channel blockers | |
| GEP20125389B (en) | Substituted pyrazole and triazole compounds as ksp inhibitors | |
| WO2004011477A3 (en) | 6,11-4-carbon bridged ketolides | |
| PH12022552495A1 (en) | Oxazolidinone compound and methods of use thereof as an antibacterial agent | |
| MX2025007492A (es) | Compuestos lipidicos y composiciones de nanoparticulas lipidicas | |
| TNSN05246A1 (en) | Use of 10-hydroxy-10, 11-dihydrocarbamazepine derivatives for the treatment of affective disorders | |
| CA2576191A1 (en) | T type calcium channel inhibitors | |
| MX2024001560A (es) | Métodos para tratar la migraña con inhibidores de cinasa activada por mitógenos (mnk). | |
| WO2006009893A3 (en) | Cancer chemotherapy | |
| MXPA05008711A (es) | Uso de r-10-hidroxi-10,11-dihidro-carbamazepina en dolor neuropatico. | |
| WO2024151638A3 (en) | Compounds for fgfrs inhibitors | |
| TW200633710A (en) | Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | |
| AP2002002494A0 (en) | Hygromycin derivatives. | |
| WO2007047881A3 (en) | Method for treating neuropathic pain | |
| DOP2004000850A (es) | Triazoles sustituidos con biarilo como bloqueantes del canal de sodio | |
| MX2024002892A (es) | Azalidos inmunomoduladores. | |
| WO2022177968A8 (en) | Therapeutic methods |